Article(id=1329914763594806219, tenantId=1146029695717560320, journalId=1319690259887390882, issueId=1329914740324807335, articleNumber=null, orderNo=null, doi=10.16522/j.cnki.cjph.2024.06.004, pmid=null, cstr=null, oa=null, hot=null, price=null, onlineType=0, articleFormat=0, articleType=null, articleTypeStr=null, receivedDate=1690819200000, receivedDateStr=2023-08-01, revisedDate=null, revisedDateStr=null, acceptedDate=null, acceptedDateStr=null, onlineDate=1795005988261, onlineDateStr=2026-11-18, pubDate=1717948800000, pubDateStr=2024-06-10, doiRegisterDate=null, doiRegisterDateStr=null, onlineIssueDate=1795005988261, onlineIssueDateStr=2026-11-18, onlineJustAcceptDate=null, onlineJustAcceptDateStr=null, onlineFirstDate=null, onlineFirstDateStr=null, sourceXml=null, magXml=null, createTime=1795005988261, creator=13701087609, updateTime=1795005988261, updator=13701087609, issue=Issue{id=1329914740324807335, tenantId=1146029695717560320, journalId=1319690259887390882, year='2024', volume='55', issue='6', pageStart='743', pageEnd='886', issueExtLink='null', onlineDate='null', pubDate='1717948800000', pubDateStr='2024-06-10', beforeIssueId=null, nextIssueId=null, price=null, status=1, issueComplete=1, articleOrder=1, issueType=-1, specialIssue=null, createTime=1795005982713, creator='13701087609', updateTime=1795136155207, updator='13701087609', preIssue=null, nextIssue=null, articleTotal=null, ext={EN=IssueExt(id=1330460723852981013, tenantId=1146029695717560320, journalId=1319690259887390882, issueId=1329914740324807335, language=EN, specialIssueTitle=, coverIllustrator=null, specialIssueEditor=, specialIssueAbout=), CN=IssueExt(id=1330460723852981014, tenantId=1146029695717560320, journalId=1319690259887390882, issueId=1329914740324807335, language=CN, specialIssueTitle=, coverIllustrator=null, specialIssueEditor=, specialIssueAbout=)}, issueFiles=null, downloadFileDto=null}, startPage=770, endPage=776, ext={EN=ArticleExt(id=1329914763817104332, articleId=1329914763594806219, tenantId=1146029695717560320, journalId=1319690259887390882, language=EN, title=New Progress in the Control of Nitrosamine Impurities in Chemical Drugs, columnId=1327671134809600231, journalTitle=Chinese Journal of Pharmaceuticals, columnName=Review, runingTitle=null, highlight=null, articleAbstract=

In view of the discovery of nitrosamine impurities in angiotensinⅡ receptor antagonists, histamine 2 receptor antagonists, antimicrobial drugs, antidiabetic drugs and other drugs, global regulatory agencies have significantly increased their supervision on nitrosamine impurities. Regulatory agencies in various countries have successively issued the corresponding guiding documents, developed risk assessment methods, and proposed control strategies for nitrosamine impurities in drugs. China has also successively introduced a series of guiding documents that are in line with the international standards to control nitrosamine impurities. However, in practical work, there are still difficulties in the generation pathways, risk assessment, and control strategies for nitrosamine impurities. This article mainly introduces the possible nitrosation pathways and formation causes of nitrosamine impurities in chemical drugs, as well as the overall requirements for the analysis methods. And the risk assessment and control strategies for nitrosamine impurities in chemical drugs proposed by the regulatory agencies in various countries are summarized, which can provide a reference for further research and control of nitrosamine impurities.

, authors=Xuan LIU1, Jingjing ZHU2, Zheng CHEN3, Yueying WANG4, authorsList=Xuan LIU, Jingjing ZHU, Zheng CHEN, Yueying WANG, authorCompany=null, correspAuthors=null, authorNote=null, correspAuthorsNote=null, copyrightStatement=null, copyrightOwner=null, extLink=null, articleAbsUrl=null, sourceXml=null, magXml=null, pdfUrl=null, pdf=null, pdfFileSize=null, pdfExtLink=null, richHtmlUrl=null, mobilePdfUrl=null, reviewReport=null, pdfFirstPage=null, abstractGraph=null, abstractGraphContent=null, abstractVideo=null, citation=null, cebUrl=null, magXmlContent=null, mapNumber=null, fund=null), CN=ArticleExt(id=1329914764618216397, articleId=1329914763594806219, tenantId=1146029695717560320, journalId=1319690259887390882, language=CN, title=化学药品中亚硝胺类杂质控制研究的新进展, columnId=1327671135019315436, journalTitle=中国医药工业杂志, columnName=综述, runingTitle=null, highlight=null, articleAbstract=

鉴于在血管紧张素Ⅱ受体拮抗药、组胺2受体拮抗药、抗微生物药和抗糖尿病药等药品中陆续发现亚硝胺类杂质,全球药品监管机构明显加大了对该类杂质的监管力度。各国药品监管机构陆续颁布了相应的指南性文件,制定了风险评估方法,提出了药品中亚硝胺类杂质的控制策略。我国也陆续出台了一系列与国际接轨的指南性文件,对亚硝胺类杂质进行控制。但实际工作中,对于化学药品中亚硝胺类杂质的产生途径、风险评估和控制策略等尚存难点。文章主要介绍了化学药品中亚硝胺类杂质形成的亚硝化途径和可能原因,及该类杂质分析方法的总体要求,同时总结了各国药品监管机构提出的药品中亚硝胺类杂质的风险评估及控制策略,为亚硝胺类杂质的进一步研究和控制提供参考。

, authors=刘璇1, 朱晶晶2, 陈正3, 王月莹4, authorsList=刘璇, 朱晶晶, 陈正, 王月莹, authorCompany=null, correspAuthors=null, authorNote=

刘璇(1984—),女,高级工程师,从事药品监管的研究。E-mail:

, correspAuthorsNote=null, copyrightStatement=null, copyrightOwner=null, extLink=null, articleAbsUrl=null, sourceXml=pGkc6ndTjLEBni6XVkrK+A==, magXml=WUxkPMX98xoRs/ZuMMO8vg==, pdfUrl=null, pdf=2N8WGiQP19rboVQ/7CNYUg==, pdfFileSize=2204199, pdfExtLink=null, richHtmlUrl=null, mobilePdfUrl=null, reviewReport=null, pdfFirstPage=null, abstractGraph=null, abstractGraphContent=null, abstractVideo=null, citation=null, cebUrl=null, magXmlContent=ot6KXDe9VZWIWE4VTSexdQ==, mapNumber=null, fund=null)}, authors=[Author(id=1329914765117338587, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329914763594806219, orderNo=0, firstName=null, middleName=null, lastName=null, nameCn=null, orcid=null, stid=null, country=null, authorPic=null, dead=0, email=liu13019730236@163.com, emailSecond=null, emailThird=null, correspondingAuthor=0, authorType=1, ext={EN=AuthorExt(id=1329914765197030365, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329914763594806219, authorId=1329914765117338587, language=EN, stringName=Xuan LIU, firstName=Xuan, middleName=null, lastName=LIU, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=1, address=1.Taizhou Huangyan District Center for ADR Monitoring, Taizhou 318020, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null), CN=AuthorExt(id=1329914765259944926, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329914763594806219, authorId=1329914765117338587, language=CN, stringName=刘璇, firstName=null, middleName=null, lastName=null, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=1, address=1.台州市黄岩区药品不良反应监测中心,浙江 台州 318020, bio={"content":"

刘璇(1984—),女,高级工程师,从事药品监管的研究。E-mail:

"}, bioImg=null, bioContent=

刘璇(1984—),女,高级工程师,从事药品监管的研究。E-mail:

, aboutCorrespAuthor=null)}, companyList=[AuthorCompany(id=1329914764794377166, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329914763594806219, xref=1., ext=[AuthorCompanyExt(id=1329914764798571471, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329914763594806219, companyId=1329914764794377166, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=1.Taizhou Huangyan District Center for ADR Monitoring, Taizhou 318020), AuthorCompanyExt(id=1329914764806960080, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329914763594806219, companyId=1329914764794377166, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=1.台州市黄岩区药品不良反应监测中心,浙江 台州 318020)])]), Author(id=1329914765331248096, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329914763594806219, orderNo=1, firstName=null, middleName=null, lastName=null, nameCn=null, orcid=null, stid=null, country=null, authorPic=null, dead=0, email=null, emailSecond=null, emailThird=null, correspondingAuthor=0, authorType=1, ext={EN=AuthorExt(id=1329914765410939874, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329914763594806219, authorId=1329914765331248096, language=EN, stringName=Jingjing ZHU, firstName=Jingjing, middleName=null, lastName=ZHU, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=2, address=2.Taizhou Institute for Food and Drug Control, Taizhou 317700, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null), CN=AuthorExt(id=1329914765465465827, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329914763594806219, authorId=1329914765331248096, language=CN, stringName=朱晶晶, firstName=null, middleName=null, lastName=null, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=2, address=2.台州市食品药品检验研究院,浙江 台州 317700, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null)}, companyList=[AuthorCompany(id=1329914764865680337, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329914763594806219, xref=2., ext=[AuthorCompanyExt(id=1329914764874068946, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329914763594806219, companyId=1329914764865680337, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=2.Taizhou Institute for Food and Drug Control, Taizhou 317700), AuthorCompanyExt(id=1329914764878263251, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329914763594806219, companyId=1329914764865680337, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=2.台州市食品药品检验研究院,浙江 台州 317700)])]), Author(id=1329914765528380389, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329914763594806219, orderNo=2, firstName=null, middleName=null, lastName=null, nameCn=null, orcid=null, stid=null, country=null, authorPic=null, dead=0, email=null, emailSecond=null, emailThird=null, correspondingAuthor=0, authorType=1, ext={EN=AuthorExt(id=1329914765599683559, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329914763594806219, authorId=1329914765528380389, language=EN, stringName=Zheng CHEN, firstName=Zheng, middleName=null, lastName=CHEN, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=3, address=3.Taizhou Administration for Market Regulation, Taizhou 317700, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null), CN=AuthorExt(id=1329914765687763944, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329914763594806219, authorId=1329914765528380389, language=CN, stringName=陈正, firstName=null, middleName=null, lastName=null, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=3, address=3.台州市市场监督管理局,浙江 台州 317700, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null)}, companyList=[AuthorCompany(id=1329914764945372116, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329914763594806219, xref=3., ext=[AuthorCompanyExt(id=1329914764953760725, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329914763594806219, companyId=1329914764945372116, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=3.Taizhou Administration for Market Regulation, Taizhou 317700), AuthorCompanyExt(id=1329914764962149334, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329914763594806219, companyId=1329914764945372116, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=3.台州市市场监督管理局,浙江 台州 317700)])]), Author(id=1329914765759067114, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329914763594806219, orderNo=3, firstName=null, middleName=null, lastName=null, nameCn=null, orcid=null, stid=null, country=null, authorPic=null, dead=0, email=null, emailSecond=null, emailThird=null, correspondingAuthor=0, authorType=1, ext={EN=AuthorExt(id=1329914765826175980, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329914763594806219, authorId=1329914765759067114, language=EN, stringName=Yueying WANG, firstName=Yueying, middleName=null, lastName=WANG, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=4, address=4.Taizhou Pharmaceutical Association, Taizhou 317700, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null), CN=AuthorExt(id=1329914765893284845, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329914763594806219, authorId=1329914765759067114, language=CN, stringName=王月莹, firstName=null, middleName=null, lastName=null, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=4, address=4.台州市药学会,浙江 台州 317700, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null)}, companyList=[AuthorCompany(id=1329914765033452503, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329914763594806219, xref=4., ext=[AuthorCompanyExt(id=1329914765041841112, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329914763594806219, companyId=1329914765033452503, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=4.Taizhou Pharmaceutical Association, Taizhou 317700), AuthorCompanyExt(id=1329914765050229721, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329914763594806219, companyId=1329914765033452503, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=4.台州市药学会,浙江 台州 317700)])])], keywords=[Keyword(id=1329914765993948142, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329914763594806219, language=EN, orderNo=1, keyword=nitrosamine impurity), Keyword(id=1329914766061057007, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329914763594806219, language=EN, orderNo=2, keyword=chemical drug), Keyword(id=1329914766149137392, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329914763594806219, language=EN, orderNo=3, keyword=quality control), Keyword(id=1329914766216246257, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329914763594806219, language=EN, orderNo=4, keyword=risk assessment), Keyword(id=1329914766279160818, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329914763594806219, language=EN, orderNo=5, keyword=control strategy), Keyword(id=1329914766350463987, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329914763594806219, language=EN, orderNo=6, keyword=research progress), Keyword(id=1329914766421767156, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329914763594806219, language=CN, orderNo=1, keyword=亚硝胺类杂质), Keyword(id=1329914766480487413, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329914763594806219, language=CN, orderNo=2, keyword=化学药品), Keyword(id=1329914766547596278, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329914763594806219, language=CN, orderNo=3, keyword=质量控制), Keyword(id=1329914766614705143, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329914763594806219, language=CN, orderNo=4, keyword=风险评估), Keyword(id=1329914766673425400, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329914763594806219, language=CN, orderNo=5, keyword=控制策略), Keyword(id=1329914766740534265, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329914763594806219, language=CN, orderNo=6, keyword=研究进展)], refs=[Reference(id=1329914766828614650, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329914763594806219, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[1], rfOrder=0, authorNames=null, journalName=null, refType=null, unstructuredReference=FDA.Announces voluntary recall of several medicines containing valsartan following detection of animpurity [EB/OL].(2022-12-18)[2024-04-01].https://www.fda.gov/news-events/press-announcements/fda-announces-voluntary-recall-several-medicines-containing-valsartan-following-detection-impurity., articleTitle=null, refAbstract=null), Reference(id=1329914766895723515, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329914763594806219, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[2], rfOrder=1, authorNames=null, journalName=null, refType=null, unstructuredReference=EMA.Temprary interim limist for NMBA, DIPNA and EIPNA impurities in sartan blood pressuremedicines [EB/OL].[2024-04-01].https://www.ema.europa.eu/en/documents/other/temporary-interim-limits-nmba-dipna-eipna-impurities-sartan-blood-pressure-medicines_en.pdf., articleTitle=null, refAbstract=null), Reference(id=1329914766975415292, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329914763594806219, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[3], rfOrder=2, authorNames=null, journalName=null, refType=null, unstructuredReference=FDA.Requests removal of all ranitidine products(Zantac)from the market [EB/OL].(2020-04-01)[2024-04-01].https://www.fda.gov/news-events/press-announcements/fda-requests-removal-all-ranitidine-products-zantac-market., articleTitle=null, refAbstract=null), Reference(id=1329914767042524157, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329914763594806219, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[4], rfOrder=3, authorNames=null, journalName=null, refType=null, unstructuredReference=FDA.Updates and press announcements on nitrosamines in rifampin and rifapentine [EB/OL].(2021-01-28)[2024-04-01].https://www.fda.gov/drugs/drug-safety-and-availability/fda-updates-and-press-announcements-nitrosamines-rifampin-and-rifapentine., articleTitle=null, refAbstract=null), Reference(id=1329914767105438718, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329914763594806219, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[5], rfOrder=4, authorNames=null, journalName=null, refType=null, unstructuredReference=ALDAWSARI F S, ALSHEHRY Y M, ALGHAMDI T S.N-nitrosodimethylamine(NDMA) contamination of ranitidine products: a review of recent fifindings [J].Food Drug Anal, 2021, 29(1): 39-45., articleTitle=null, refAbstract=null), Reference(id=1329914767168353279, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329914763594806219, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[6], rfOrder=5, authorNames=null, journalName=null, refType=null, unstructuredReference=HSA.Recalls three out of 46 metformin medicines [EB/OL].(2019-12-04)[2024-04-01].https://www.hsa.gov.sg/announcements/news/hsa-recalls-three-out-of-46-metformin-medicines., articleTitle=null, refAbstract=null), Reference(id=1329914767235462144, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329914763594806219, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[7], rfOrder=6, authorNames=null, journalName=null, refType=null, unstructuredReference=FDA.Pfizer voluntary nationwide recall of lots of accuretic(quinapril HCl/hydrochlorothiazide), quinapril and hydrochlorothiazide tablets, and quinapril HCl/hydrochloro-thiazide tablets due to N-nitroso-quinapril content [EB/OL].(2022-03-22)[2024-04-01].https://www.fda.gov/safety/recalls-market-withdrawals-safety-alerts/pfizer-voluntary-nationwide-recall-lots-accuretic-quinapril-hclhydrochlorothiazide-quinapril-and., articleTitle=null, refAbstract=null), Reference(id=1329914767323541504, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329914763594806219, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[8], rfOrder=7, authorNames=null, journalName=null, refType=null, unstructuredReference=FDA.Pfizer recalls inderal-LA(propranolol hydrochloride)capsules due to a nitrosamine impurity [EB/OL].(2022-03-01)[2024-04-01].https://recalls-rappels.canada.ca/en/alert-recall/pfizer-recalls-inderal-propranolol-hydrochloride-capsules-due-nitrosamine-impurity., articleTitle=null, refAbstract=null), Reference(id=1329914767386456065, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329914763594806219, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[9], rfOrder=8, authorNames=null, journalName=null, refType=null, unstructuredReference=FDA.FDA works to avoid shortage of sitagliptin following detection of nitrosamine impurity [EB/OL].(2022-08-09)[2024-04-01].https://www.fda.gov/drugs/drug-safety-and-availability/fda-works-avoid-shortage-sitagliptin-following-detection-nitrosamine-impurity., articleTitle=null, refAbstract=null), Reference(id=1329914767449370626, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329914763594806219, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[10], rfOrder=9, authorNames=null, journalName=null, refType=null, unstructuredReference=CANADA.Amitriptyline antidepressant drugs recalled because of a nitrosamine impurity [EB/OL].(2023-02-07)[2024-04-01].https://recalls-rappels.canada.ca/en/alert-recall/amitriptyline-antidepressant-drugs-recalled-because-nitrosamine-impurity., articleTitle=null, refAbstract=null), Reference(id=1329914767512285187, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329914763594806219, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[11], rfOrder=10, authorNames=null, journalName=null, refType=null, unstructuredReference=FDA.Ascend laboratories LLC issues voluntary nation-wide recall of dabigatran etexilate capsules, USP 75 mg and 150 mg, due to the detection of N-nitroso-dabigatran(NDAB)impurity [EB/OL].(2023-03-22)[2024-04-01].https://www.fda.gov/safety/recalls-market-withdrawals-safety-alerts/ascend-laboratories-llc-issues-voluntary-nationwide-recall-dabigatran-etexilate-capsules-usp-75-mg., articleTitle=null, refAbstract=null), Reference(id=1329914767566811140, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329914763594806219, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[12], rfOrder=11, authorNames=null, journalName=null, refType=null, unstructuredReference=国家药品监督管理局.世界卫生组织国际癌症研究机构致癌物清单[EB/OL].(2017-10-27)[2024-04-01].https://www.nmpa.gov.cn/xxgk/mtbd/20171030163101383.html., articleTitle=null, refAbstract=null), Reference(id=1329914767638114309, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329914763594806219, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[13], rfOrder=12, authorNames=null, journalName=null, refType=null, unstructuredReference=ICH.M7(R1) Assessment and control of DNA reactive(mutagenic) impurities in pharmaceuticals of limit potential carcinogenic risk [EB/OL].(2017-03-31)[2024-04-01].https://www.fda.gov/regulatory-information/search-fda-guidance-documents/m7r1-assessmentand-control-dna-reactive-mutagenic-impuritiespharmaceuticals-limit-potential., articleTitle=null, refAbstract=null), Reference(id=1329914767701028870, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329914763594806219, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[14], rfOrder=13, authorNames=null, journalName=null, refType=null, unstructuredReference=FDA.Control of nitrosamine impurities in human drugs guidance for industry [EB/OL].(2021-02-24)[2024-04-01].https://www.fda.gov/regulatory-information/search-fda-guidance-documents/control-nitrosamine-impurities-human-drugs., articleTitle=null, refAbstract=null), Reference(id=1329914767759749127, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329914763594806219, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[15], rfOrder=14, authorNames=null, journalName=null, refType=null, unstructuredReference=EMA.Nitrosamines EMEA-H-A5(3)-1490-Questions and answers for marketing authorisation holders/applicants on the CHMP Opinion for the Article 5(3) of Regulation(EC) No 726/2004 referral on nitrosamine impurities in human medicinal products [EB/OL].[2024-04-01].https://www.ema.europa.eu/en/documents/referral/nitrosamines-emea-h-a53-1490-questions-answers-marketing-authorisation-holders-applicants-chmp-opinion-article-53-regulation-ec-no-726-2004-referral-nitrosamine-impurities-human-medicinal-products_en.pdf., articleTitle=null, refAbstract=null), Reference(id=1329914767826857992, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329914763594806219, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[16], rfOrder=15, authorNames=null, journalName=null, refType=null, unstructuredReference=EMA.Lessons learnt from presence of N-nitrosamine impurities in Sartan medicines [EB/OL].(2020-06-23)[2024-04-01].https://www.ema.europa.eu/en/documents/other/lessons-learnt-presence-n-nitrosamine-impurities-sartan-medicines-implementation-plan_en.pdf., articleTitle=null, refAbstract=null), Reference(id=1329914767885578249, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329914763594806219, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[17], rfOrder=16, authorNames=null, journalName=null, refType=null, unstructuredReference=EMA.Nitrosamines EMEA-H-A5(3)-1490-Assessment report EMA/369136/2020 [EB/OL].(2020-09-07)[2024-04-01].https://www.ema.europa.eu/en/documents/referral/nitrosamines-emea-h-a53-1490-assessment-report_en.pdf., articleTitle=null, refAbstract=null), Reference(id=1329914767948492810, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329914763594806219, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[18], rfOrder=17, authorNames=null, journalName=null, refType=null, unstructuredReference=国家药品监督管理局药品审评中心.国家药审中心关于发布《化学药物中亚硝胺类杂质研究技术指导原则(试行)》的通告[EB/OL].(2020-05-8)[2024-04-01].https://www.cde.org.cn/main/news/viewInfoCommon/776b663787e-c5a60ac744071c3714d5a., articleTitle=null, refAbstract=null), Reference(id=1329914768011407371, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329914763594806219, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[19], rfOrder=18, authorNames=null, journalName=null, refType=null, unstructuredReference=NASR N E H, METWALY G M, AHMED E O, et al.Investigating the root cause of N-nitrosodimethylamine formation in metformin pharmaceutical products [J].Expert Opin Drug Saf, 2021, 20(7): 1-8., articleTitle=null, refAbstract=null), Reference(id=1329914768082710540, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329914763594806219, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[20], rfOrder=19, authorNames=null, journalName=null, refType=null, unstructuredReference=JIREŠ J, GIBALA P, KALÁŠEK S, et al.The determination of two analogues of 4-(azidomethyl)-1,1'-biphenyl as potential genotoxic impurities in the active pharmaceutical ingredient of several sartans containing a tetrazole group [J].J Pham Biomed Anal, 2021, 205: 114300-114306., articleTitle=null, refAbstract=null), Reference(id=1329914768154013709, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329914763594806219, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[21], rfOrder=20, authorNames=null, journalName=null, refType=null, unstructuredReference=WISUT W, SIRIWAN N, KACHATHONG N, et al.An update on the current status and prospects of nitrosation pathways and possible root causes of nitrosamine formation in various pharmaceuticals [J].Saudi Pharm J, 2023, 31: 295-311., articleTitle=null, refAbstract=null), Reference(id=1329914768225316878, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329914763594806219, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[22], rfOrder=21, authorNames=null, journalName=null, refType=null, unstructuredReference=EDQM.Launches a public consultation on a new general chapter for the analysis of N-nitrosamines [EB/OL].(2020-07-04)[2024-04-01].https://www.edqm.eu/en/news/ph-eur-launches-public-consultation-new-general-chapter-analysis-n-nitrosamines., articleTitle=null, refAbstract=null), Reference(id=1329914768292425743, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329914763594806219, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[23], rfOrder=22, authorNames=null, journalName=null, refType=null, unstructuredReference=FDA.FDA updates table of interim limits for nitrosamine impurities in ARBs [EB/OL].(2019-02-28) [2024-04-01].https://www.fda.gov/drugs/drug-safety-and-availability/fda-updates-and-press-announcements-angiotensin-ii-receptor-blocker-arb-recalls-valsartan-losartan., articleTitle=null, refAbstract=null), Reference(id=1329914768355340304, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329914763594806219, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[24], rfOrder=23, authorNames=null, journalName=null, refType=null, unstructuredReference=张芮腾,青旺旺,廖星星,等.药物中基因毒性杂质检测方法研究进展[J].中国医院药学杂志,2021,41(3):327-332., articleTitle=null, refAbstract=null), Reference(id=1329914768426643473, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329914763594806219, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[25], rfOrder=24, authorNames=null, journalName=null, refType=null, unstructuredReference=邓鸣,曾庆花,梁秋霞,等.HPLC-MS/MS法测定注射用盐酸头孢甲肟中7种N-亚硝胺类杂质[J].中南药学,2023,21(8):2178-12181., articleTitle=null, refAbstract=null), Reference(id=1329914768510529554, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329914763594806219, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[26], rfOrder=25, authorNames=null, journalName=null, refType=null, unstructuredReference=陈丹,汪嘉丽.缬沙坦原料药中7个亚硝胺类基因毒性杂质测定方法的建立及评价[J].中国药物经济学,2022,17(7):97-100., articleTitle=null, refAbstract=null), Reference(id=1329914768577638419, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329914763594806219, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[27], rfOrder=26, authorNames=null, journalName=null, refType=null, unstructuredReference=李俊,张璐,张瑄,等.GC-MS/MS测定头孢菌素类药物中8种N-亚硝胺类基因毒性杂质[J].中国药师,2022,25(2):350-354., articleTitle=null, refAbstract=null), Reference(id=1329914768648941588, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329914763594806219, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[28], rfOrder=27, authorNames=null, journalName=null, refType=null, unstructuredReference=袁松,冯玉飞,于颖,等.UPLC-MS/MS法测定奥美沙坦酯中7个亚硝胺类基因毒性杂质[J].中国药师,2021,44(2):356-361., articleTitle=null, refAbstract=null)], funds=null, companyList=[AuthorCompany(id=1329914764794377166, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329914763594806219, xref=1., ext=[AuthorCompanyExt(id=1329914764798571471, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329914763594806219, companyId=1329914764794377166, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=1.Taizhou Huangyan District Center for ADR Monitoring, Taizhou 318020), AuthorCompanyExt(id=1329914764806960080, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329914763594806219, companyId=1329914764794377166, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=1.台州市黄岩区药品不良反应监测中心,浙江 台州 318020)]), AuthorCompany(id=1329914764865680337, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329914763594806219, xref=2., ext=[AuthorCompanyExt(id=1329914764874068946, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329914763594806219, companyId=1329914764865680337, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=2.Taizhou Institute for Food and Drug Control, Taizhou 317700), AuthorCompanyExt(id=1329914764878263251, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329914763594806219, companyId=1329914764865680337, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=2.台州市食品药品检验研究院,浙江 台州 317700)]), AuthorCompany(id=1329914764945372116, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329914763594806219, xref=3., ext=[AuthorCompanyExt(id=1329914764953760725, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329914763594806219, companyId=1329914764945372116, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=3.Taizhou Administration for Market Regulation, Taizhou 317700), AuthorCompanyExt(id=1329914764962149334, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329914763594806219, companyId=1329914764945372116, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=3.台州市市场监督管理局,浙江 台州 317700)]), AuthorCompany(id=1329914765033452503, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329914763594806219, xref=4., ext=[AuthorCompanyExt(id=1329914765041841112, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329914763594806219, companyId=1329914765033452503, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=4.Taizhou Pharmaceutical Association, Taizhou 317700), AuthorCompanyExt(id=1329914765050229721, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329914763594806219, companyId=1329914765033452503, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=4.台州市药学会,浙江 台州 317700)])], figs=null, attaches=null, journal=Journal(id=1319689822849302687, delFlag=0, nameCn=中国医药工业杂志, nameEn=Chinese Journal of Pharmaceuticals, nameHistory1=null, nameHistory2=null, issn=1001-8255, eissn=null, cn=31-1243/R, coden=ZYGZEA, periodic=0, language=CN, oaType=null, ccby=null, superviseOffice=null, ownerOffice=null, pubOffice=null, editorOffice=null, officeType=null, aims=null, clcCode=null, officeProv=null, officeCity=null, officeAddr=null, officeZip=null, officeEmail=null, officePhone=null, editDirector=null, officeDirector=null, officeDirectorPhone=null, officeStaffNum=null, officeEmpNum=null, coverPicUrl=etiWDuwx2KO274LHw88KJA==, journalPrice=null, startedYear=null, abbrevIsoEn=Chinese Journal of Pharmaceuticals, journalRemark=null, publicationField=null, createdTime=1792568172420, updatedTime=1792747450744, createdBy=18614031015, updatedBy=13701087609, firstLetterCn=Z, firstLetterEn=Z, subjectCode=Medical and Pharmaceutical Sciences, subjectName=null, subjectCodeEn=Medical and Pharmaceutical Sciences, subjectNameEn=null, picCn=etiWDuwx2KO274LHw88KJA==, picEn=ip9NF4dK57AmNrCiZ6hmdw==, jcr=null, cjcr=null, exts=[JournalExt(id=1320441770761105589, language=CN, name=中国医药工业杂志, nameHistory1=null, nameHistory2=null, managedBy=, sponsoredBy=, publishedBy=, editorOffice=, officeProv=null, officeCity=null, officeAddr=, officeZip=, editDirector=, officeDirector=null, officePhone=null, coverPicUrl=null, journalRemark=, submitArticleUrl=null, websiteUrl=, createdTime=1792747450771, updatedTime=1792747450771, createdBy=13701087609, updatedBy=13701087609, submissionGuidelinesUrl=, submissionAuthorUrl=https://zgyygyauthor.cast.org.cn/webm, submissionEditorUrl=https://zgyygyeditor.cast.org.cn/webm, submissionReviewUrl=https://zgyygyauthor.cast.org.cn/webm, submissionCeEditorUrl=https://zgyygyeditor.cast.org.cn/webm, submissionAeEditorUrl=https://zgyygyeditor.cast.org.cn/webm, option={"copyright":""}), JournalExt(id=1320441770819825846, language=EN, name=Chinese Journal of Pharmaceuticals, nameHistory1=null, nameHistory2=null, managedBy=, sponsoredBy=, publishedBy=, editorOffice=, officeProv=null, officeCity=null, officeAddr=, officeZip=, editDirector=, officeDirector=null, officePhone=null, coverPicUrl=null, journalRemark=, submitArticleUrl=null, websiteUrl=, createdTime=1792747450785, updatedTime=1792747450785, createdBy=13701087609, updatedBy=13701087609, submissionGuidelinesUrl=, submissionAuthorUrl=https://zgyygyauthor.cast.org.cn/webm, submissionEditorUrl=https://zgyygyeditor.cast.org.cn/webm, submissionReviewUrl=https://zgyygyauthor.cast.org.cn/webm, submissionCeEditorUrl=https://zgyygyeditor.cast.org.cn/webm, submissionAeEditorUrl=https://zgyygyeditor.cast.org.cn/webm, option={"copyright":""})], databaseList=null, tenantJournalId=1319690259887390882, websiteList=[Website(id=1319720771623174732, webName=null, webTitle=null, webDomain=null, webCopyrigh=null, webIpcNo=null, seoTitle=null, seoKeywords=null, seoDescription=null, tenantJournalId=null, journalId=1319690259887390882, journalNameCn=null, journalNameEn=null, grayFlag=null, tenantId=1146029695717560320, platformId=null, journalGroupId=null, journalGroupNameCn=null, journalGroupNameEn=null, type=1, domain=https://castjournals.cast.org.cn/joweb/zgyygy/CN, language=CN, createTime=1792575551181, createBy=18614031015, updateTime=1792746040843, updateBy=18614031015, name=中国医药工业杂志-中文, tplId=1146099689490845704, title=中国医药工业杂志, delFlag=0, indexPage=/home, props=[WebsiteProps(id=1321428487504769041, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1319720771623174732, code=articleTextType, value=kx, createTime=1792982702375, updateTime=1792982702375, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428487475408910, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1319720771623174732, code=banner, value=https://castjournals.cast.org.cn/joweb/zgyygy/CN/file/pic?fileId=i/3+mr8MqWvs6ArWn9VK7w==, createTime=1792982702368, updateTime=1792982702368, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428487538323476, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1319720771623174732, code=grayFlag, value=0, createTime=1792982702383, updateTime=1792982702383, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428487462825997, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1319720771623174732, code=logo, value=https://castjournals.cast.org.cn/joweb/zgyygy/CN/file/pic?fileId=7mfvc3zMp/tsQUIOlJrNFQ==, createTime=1792982702365, updateTime=1792982702365, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428487571877910, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1319720771623174732, code=minRunFlag, value=0, createTime=1792982702391, updateTime=1792982702391, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428487496380432, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1319720771623174732, code=picServerUrl, value=https://castjournals.cast.org.cn/joweb/zgyygy/CN/file/pic, createTime=1792982702373, updateTime=1792982702373, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428487563489301, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1319720771623174732, code=silenceFlag, value=0, createTime=1792982702389, updateTime=1792982702389, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428487483797519, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1319720771623174732, code=staticResourcePath, value=https://castjournals.cast.org.cn/joweb/cast_kjdb_cn_619/, createTime=1792982702370, updateTime=1792982702370, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428487517351954, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1319720771623174732, code=themeColor, value=null, createTime=1792982702378, updateTime=1792982702378, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428487525740563, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1319720771623174732, code=themeStyle, value=.style-1 .main-menu ul>li { margin-right: 18px; } @media (max-width: 1442px) { .style-1 .main-menu ul>li a { font-size: 16px; padding: 10px 0; } }, createTime=1792982702380, updateTime=1792982702380, creator=18614031015, updator=18614031015)]), Website(id=1319720771702866512, webName=null, webTitle=null, webDomain=null, webCopyrigh=null, webIpcNo=null, seoTitle=null, seoKeywords=null, seoDescription=null, tenantJournalId=null, journalId=1319690259887390882, journalNameCn=null, journalNameEn=null, grayFlag=null, tenantId=1146029695717560320, platformId=null, journalGroupId=null, journalGroupNameCn=null, journalGroupNameEn=null, type=1, domain=https://castjournals.cast.org.cn/joweb/zgyygy/EN, language=EN, createTime=1792575551200, createBy=18614031015, updateTime=1792746037543, updateBy=18614031015, name=中国医药工业杂志-英文, tplId=1146101810881728533, title=Chinese Journal of Pharmaceuticals, delFlag=0, indexPage=/home, props=[WebsiteProps(id=1321428509638111261, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1319720771702866512, code=articleTextType, value=kx, createTime=1792982707652, updateTime=1792982707652, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428509579391002, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1319720771702866512, code=banner, value=https://castjournals.cast.org.cn/joweb/zgyygy/EN/file/pic?fileId=i/3+mr8MqWvs6ArWn9VK7w==, createTime=1792982707638, updateTime=1792982707638, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428509680054304, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1319720771702866512, code=grayFlag, value=0, createTime=1792982707662, updateTime=1792982707662, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428509566808089, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1319720771702866512, code=logo, value=https://castjournals.cast.org.cn/joweb/zgyygy/EN/file/pic?fileId=7mfvc3zMp/tsQUIOlJrNFQ==, createTime=1792982707635, updateTime=1792982707635, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428509701025826, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1319720771702866512, code=minRunFlag, value=0, createTime=1792982707667, updateTime=1792982707667, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428509629722652, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1319720771702866512, code=picServerUrl, value=https://castjournals.cast.org.cn/joweb/zgyygy/EN/file/pic, createTime=1792982707650, updateTime=1792982707650, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428509688442913, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1319720771702866512, code=silenceFlag, value=0, createTime=1792982707664, updateTime=1792982707664, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428509587779611, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1319720771702866512, code=staticResourcePath, value=https://castjournals.cast.org.cn/joweb/cast_kjdb_en_623/, createTime=1792982707640, updateTime=1792982707640, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428509663277086, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1319720771702866512, code=themeColor, value=null, createTime=1792982707658, updateTime=1792982707658, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428509671665695, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1319720771702866512, code=themeStyle, value=.style-1 .main-menu ul>li { margin-right: 18px; } @media (max-width: 1442px) { .style-1 .main-menu ul>li a { font-size: 16px; padding: 10px 0; } }, createTime=1792982707660, updateTime=1792982707660, creator=18614031015, updator=18614031015)])], journalTitle=中国医药工业杂志, weixinUrl=null, journalUrl=http://www.cjph.com.cn/, iacademicId=null, status=1, seqNo=null, journalTitleEn=Chinese Journal of Pharmaceuticals, journalPhotoCn=etiWDuwx2KO274LHw88KJA==, journalPhotoEn=ip9NF4dK57AmNrCiZ6hmdw==, journalFirstLetter=Z, journalRecommend=null, journalNew=null, journalCollection=null, jcrJf=null, cjcrJf=null, jcrJfStr=null, cjcrJfStr=null, submissionFirstDecision=null, sciSubjectClassification=null, casSubjectClassification=null, citeScore=null, totalCitationFrequency=null, icpCode=null, psCode=null, advertisingLicenseCode=null, copyrightInformation=null, country=null, option=, provinceCode=null, provinceName=null, collectFlag=false, interPubPlatform=, interPubPlatformUrl=null), detailUrlCn=https://castjournals.cast.org.cn/joweb/zgyygy/CN/10.16522/j.cnki.cjph.2024.06.004, detailUrlEn=https://castjournals.cast.org.cn/joweb/zgyygy/EN/10.16522/j.cnki.cjph.2024.06.004, pdfUrlCn=https://castjournals.cast.org.cn/joweb/zgyygy/CN/PDF/10.16522/j.cnki.cjph.2024.06.004, pdfUrlEn=https://castjournals.cast.org.cn/joweb/zgyygy/EN/PDF/10.16522/j.cnki.cjph.2024.06.004, aliStartDate=0, aliEndDate=0, collectionFlag=false, citedCount=null, citedUrl=null, previewStatus=0, delFlag=0, hasFullText=0, orderTime=1717948800000, fullTextJson=null, articleText=null, reference=null)
收藏切换
化学药品中亚硝胺类杂质控制研究的新进展
刘璇 1 , 朱晶晶 2 , 陈正 3 , 王月莹 4
中国医药工业杂志 | 综述 2024,55(6): 770-776
收起
收藏切换
中国医药工业杂志 |综述 2024 , 55 (6) : 770 -776
化学药品中亚硝胺类杂质控制研究的新进展
全屏
[Author(id=1329914765117338587, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329914763594806219, orderNo=0, firstName=null, middleName=null, lastName=null, nameCn=null, orcid=null, stid=null, country=null, authorPic=null, dead=0, email=liu13019730236@163.com, emailSecond=null, emailThird=null, correspondingAuthor=0, authorType=1, ext={EN=AuthorExt(id=1329914765197030365, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329914763594806219, authorId=1329914765117338587, language=EN, stringName=Xuan LIU, firstName=Xuan, middleName=null, lastName=LIU, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=1, address=1.Taizhou Huangyan District Center for ADR Monitoring, Taizhou 318020, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null), CN=AuthorExt(id=1329914765259944926, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329914763594806219, authorId=1329914765117338587, language=CN, stringName=刘璇, firstName=null, middleName=null, lastName=null, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=1, address=1.台州市黄岩区药品不良反应监测中心,浙江 台州 318020, bio={"content":"

刘璇(1984—),女,高级工程师,从事药品监管的研究。E-mail:

"}, bioImg=null, bioContent=

刘璇(1984—),女,高级工程师,从事药品监管的研究。E-mail:

, aboutCorrespAuthor=null)}, companyList=[AuthorCompany(id=1329914764794377166, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329914763594806219, xref=1., ext=[AuthorCompanyExt(id=1329914764798571471, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329914763594806219, companyId=1329914764794377166, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=1.Taizhou Huangyan District Center for ADR Monitoring, Taizhou 318020), AuthorCompanyExt(id=1329914764806960080, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329914763594806219, companyId=1329914764794377166, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=1.台州市黄岩区药品不良反应监测中心,浙江 台州 318020)])]), Author(id=1329914765331248096, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329914763594806219, orderNo=1, firstName=null, middleName=null, lastName=null, nameCn=null, orcid=null, stid=null, country=null, authorPic=null, dead=0, email=null, emailSecond=null, emailThird=null, correspondingAuthor=0, authorType=1, ext={EN=AuthorExt(id=1329914765410939874, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329914763594806219, authorId=1329914765331248096, language=EN, stringName=Jingjing ZHU, firstName=Jingjing, middleName=null, lastName=ZHU, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=2, address=2.Taizhou Institute for Food and Drug Control, Taizhou 317700, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null), CN=AuthorExt(id=1329914765465465827, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329914763594806219, authorId=1329914765331248096, language=CN, stringName=朱晶晶, firstName=null, middleName=null, lastName=null, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=2, address=2.台州市食品药品检验研究院,浙江 台州 317700, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null)}, companyList=[AuthorCompany(id=1329914764865680337, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329914763594806219, xref=2., ext=[AuthorCompanyExt(id=1329914764874068946, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329914763594806219, companyId=1329914764865680337, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=2.Taizhou Institute for Food and Drug Control, Taizhou 317700), AuthorCompanyExt(id=1329914764878263251, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329914763594806219, companyId=1329914764865680337, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=2.台州市食品药品检验研究院,浙江 台州 317700)])]), Author(id=1329914765528380389, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329914763594806219, orderNo=2, firstName=null, middleName=null, lastName=null, nameCn=null, orcid=null, stid=null, country=null, authorPic=null, dead=0, email=null, emailSecond=null, emailThird=null, correspondingAuthor=0, authorType=1, ext={EN=AuthorExt(id=1329914765599683559, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329914763594806219, authorId=1329914765528380389, language=EN, stringName=Zheng CHEN, firstName=Zheng, middleName=null, lastName=CHEN, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=3, address=3.Taizhou Administration for Market Regulation, Taizhou 317700, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null), CN=AuthorExt(id=1329914765687763944, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329914763594806219, authorId=1329914765528380389, language=CN, stringName=陈正, firstName=null, middleName=null, lastName=null, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=3, address=3.台州市市场监督管理局,浙江 台州 317700, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null)}, companyList=[AuthorCompany(id=1329914764945372116, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329914763594806219, xref=3., ext=[AuthorCompanyExt(id=1329914764953760725, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329914763594806219, companyId=1329914764945372116, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=3.Taizhou Administration for Market Regulation, Taizhou 317700), AuthorCompanyExt(id=1329914764962149334, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329914763594806219, companyId=1329914764945372116, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=3.台州市市场监督管理局,浙江 台州 317700)])]), Author(id=1329914765759067114, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329914763594806219, orderNo=3, firstName=null, middleName=null, lastName=null, nameCn=null, orcid=null, stid=null, country=null, authorPic=null, dead=0, email=null, emailSecond=null, emailThird=null, correspondingAuthor=0, authorType=1, ext={EN=AuthorExt(id=1329914765826175980, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329914763594806219, authorId=1329914765759067114, language=EN, stringName=Yueying WANG, firstName=Yueying, middleName=null, lastName=WANG, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=4, address=4.Taizhou Pharmaceutical Association, Taizhou 317700, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null), CN=AuthorExt(id=1329914765893284845, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329914763594806219, authorId=1329914765759067114, language=CN, stringName=王月莹, firstName=null, middleName=null, lastName=null, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=4, address=4.台州市药学会,浙江 台州 317700, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null)}, companyList=[AuthorCompany(id=1329914765033452503, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329914763594806219, xref=4., ext=[AuthorCompanyExt(id=1329914765041841112, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329914763594806219, companyId=1329914765033452503, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=4.Taizhou Pharmaceutical Association, Taizhou 317700), AuthorCompanyExt(id=1329914765050229721, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329914763594806219, companyId=1329914765033452503, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=4.台州市药学会,浙江 台州 317700)])])]
刘璇1 , 朱晶晶2, 陈正3, 王月莹4
作者信息
  • 1.台州市黄岩区药品不良反应监测中心,浙江 台州 318020
  • 2.台州市食品药品检验研究院,浙江 台州 317700
  • 3.台州市市场监督管理局,浙江 台州 317700
  • 4.台州市药学会,浙江 台州 317700
作者简介:

刘璇(1984—),女,高级工程师,从事药品监管的研究。E-mail:

New Progress in the Control of Nitrosamine Impurities in Chemical Drugs
Xuan LIU1 , Jingjing ZHU2, Zheng CHEN3, Yueying WANG4
Affiliations
  • 1.Taizhou Huangyan District Center for ADR Monitoring, Taizhou 318020
  • 2.Taizhou Institute for Food and Drug Control, Taizhou 317700
  • 3.Taizhou Administration for Market Regulation, Taizhou 317700
  • 4.Taizhou Pharmaceutical Association, Taizhou 317700
出版时间: 2024-06-10 doi: 10.16522/j.cnki.cjph.2024.06.004
文章导航
收藏切换

鉴于在血管紧张素Ⅱ受体拮抗药、组胺2受体拮抗药、抗微生物药和抗糖尿病药等药品中陆续发现亚硝胺类杂质,全球药品监管机构明显加大了对该类杂质的监管力度。各国药品监管机构陆续颁布了相应的指南性文件,制定了风险评估方法,提出了药品中亚硝胺类杂质的控制策略。我国也陆续出台了一系列与国际接轨的指南性文件,对亚硝胺类杂质进行控制。但实际工作中,对于化学药品中亚硝胺类杂质的产生途径、风险评估和控制策略等尚存难点。文章主要介绍了化学药品中亚硝胺类杂质形成的亚硝化途径和可能原因,及该类杂质分析方法的总体要求,同时总结了各国药品监管机构提出的药品中亚硝胺类杂质的风险评估及控制策略,为亚硝胺类杂质的进一步研究和控制提供参考。

亚硝胺类杂质  /  化学药品  /  质量控制  /  风险评估  /  控制策略  /  研究进展

In view of the discovery of nitrosamine impurities in angiotensinⅡ receptor antagonists, histamine 2 receptor antagonists, antimicrobial drugs, antidiabetic drugs and other drugs, global regulatory agencies have significantly increased their supervision on nitrosamine impurities. Regulatory agencies in various countries have successively issued the corresponding guiding documents, developed risk assessment methods, and proposed control strategies for nitrosamine impurities in drugs. China has also successively introduced a series of guiding documents that are in line with the international standards to control nitrosamine impurities. However, in practical work, there are still difficulties in the generation pathways, risk assessment, and control strategies for nitrosamine impurities. This article mainly introduces the possible nitrosation pathways and formation causes of nitrosamine impurities in chemical drugs, as well as the overall requirements for the analysis methods. And the risk assessment and control strategies for nitrosamine impurities in chemical drugs proposed by the regulatory agencies in various countries are summarized, which can provide a reference for further research and control of nitrosamine impurities.

nitrosamine impurity  /  chemical drug  /  quality control  /  risk assessment  /  control strategy  /  research progress
刘璇, 朱晶晶, 陈正, 王月莹. 化学药品中亚硝胺类杂质控制研究的新进展. 中国医药工业杂志, 2024 , 55 (6) : 770 -776 . DOI: 10.16522/j.cnki.cjph.2024.06.004
Xuan LIU, Jingjing ZHU, Zheng CHEN, Yueying WANG. New Progress in the Control of Nitrosamine Impurities in Chemical Drugs[J]. Chinese Journal of Pharmaceuticals, 2024 , 55 (6) : 770 -776 . DOI: 10.16522/j.cnki.cjph.2024.06.004

参考文献 引证文献
排序方式:
[1]
FDA.Announces voluntary recall of several medicines containing valsartan following detection of animpurity [EB/OL].(2022-12-18)[2024-04-01].https://www.fda.gov/news-events/press-announcements/fda-announces-voluntary-recall-several-medicines-containing-valsartan-following-detection-impurity.
[2]
EMA.Temprary interim limist for NMBA, DIPNA and EIPNA impurities in sartan blood pressuremedicines [EB/OL].[2024-04-01].https://www.ema.europa.eu/en/documents/other/temporary-interim-limits-nmba-dipna-eipna-impurities-sartan-blood-pressure-medicines_en.pdf.
[3]
FDA.Requests removal of all ranitidine products(Zantac)from the market [EB/OL].(2020-04-01)[2024-04-01].https://www.fda.gov/news-events/press-announcements/fda-requests-removal-all-ranitidine-products-zantac-market.
[4]
FDA.Updates and press announcements on nitrosamines in rifampin and rifapentine [EB/OL].(2021-01-28)[2024-04-01].https://www.fda.gov/drugs/drug-safety-and-availability/fda-updates-and-press-announcements-nitrosamines-rifampin-and-rifapentine.
[5]
ALDAWSARI F S, ALSHEHRY Y M, ALGHAMDI T S.N-nitrosodimethylamine(NDMA) contamination of ranitidine products: a review of recent fifindings [J].Food Drug Anal, 2021, 29(1): 39-45.
[6]
HSA.Recalls three out of 46 metformin medicines [EB/OL].(2019-12-04)[2024-04-01].https://www.hsa.gov.sg/announcements/news/hsa-recalls-three-out-of-46-metformin-medicines.
[7]
FDA.Pfizer voluntary nationwide recall of lots of accuretic(quinapril HCl/hydrochlorothiazide), quinapril and hydrochlorothiazide tablets, and quinapril HCl/hydrochloro-thiazide tablets due to N-nitroso-quinapril content [EB/OL].(2022-03-22)[2024-04-01].https://www.fda.gov/safety/recalls-market-withdrawals-safety-alerts/pfizer-voluntary-nationwide-recall-lots-accuretic-quinapril-hclhydrochlorothiazide-quinapril-and.
[8]
FDA.Pfizer recalls inderal-LA(propranolol hydrochloride)capsules due to a nitrosamine impurity [EB/OL].(2022-03-01)[2024-04-01].https://recalls-rappels.canada.ca/en/alert-recall/pfizer-recalls-inderal-propranolol-hydrochloride-capsules-due-nitrosamine-impurity.
[9]
FDA.FDA works to avoid shortage of sitagliptin following detection of nitrosamine impurity [EB/OL].(2022-08-09)[2024-04-01].https://www.fda.gov/drugs/drug-safety-and-availability/fda-works-avoid-shortage-sitagliptin-following-detection-nitrosamine-impurity.
[10]
CANADA.Amitriptyline antidepressant drugs recalled because of a nitrosamine impurity [EB/OL].(2023-02-07)[2024-04-01].https://recalls-rappels.canada.ca/en/alert-recall/amitriptyline-antidepressant-drugs-recalled-because-nitrosamine-impurity.
[11]
FDA.Ascend laboratories LLC issues voluntary nation-wide recall of dabigatran etexilate capsules, USP 75 mg and 150 mg, due to the detection of N-nitroso-dabigatran(NDAB)impurity [EB/OL].(2023-03-22)[2024-04-01].https://www.fda.gov/safety/recalls-market-withdrawals-safety-alerts/ascend-laboratories-llc-issues-voluntary-nationwide-recall-dabigatran-etexilate-capsules-usp-75-mg.
[12]
国家药品监督管理局.世界卫生组织国际癌症研究机构致癌物清单[EB/OL].(2017-10-27)[2024-04-01].https://www.nmpa.gov.cn/xxgk/mtbd/20171030163101383.html.
[13]
ICH.M7(R1) Assessment and control of DNA reactive(mutagenic) impurities in pharmaceuticals of limit potential carcinogenic risk [EB/OL].(2017-03-31)[2024-04-01].https://www.fda.gov/regulatory-information/search-fda-guidance-documents/m7r1-assessmentand-control-dna-reactive-mutagenic-impuritiespharmaceuticals-limit-potential.
[14]
FDA.Control of nitrosamine impurities in human drugs guidance for industry [EB/OL].(2021-02-24)[2024-04-01].https://www.fda.gov/regulatory-information/search-fda-guidance-documents/control-nitrosamine-impurities-human-drugs.
[15]
EMA.Nitrosamines EMEA-H-A5(3)-1490-Questions and answers for marketing authorisation holders/applicants on the CHMP Opinion for the Article 5(3) of Regulation(EC) No 726/2004 referral on nitrosamine impurities in human medicinal products [EB/OL].[2024-04-01].https://www.ema.europa.eu/en/documents/referral/nitrosamines-emea-h-a53-1490-questions-answers-marketing-authorisation-holders-applicants-chmp-opinion-article-53-regulation-ec-no-726-2004-referral-nitrosamine-impurities-human-medicinal-products_en.pdf.
[16]
EMA.Lessons learnt from presence of N-nitrosamine impurities in Sartan medicines [EB/OL].(2020-06-23)[2024-04-01].https://www.ema.europa.eu/en/documents/other/lessons-learnt-presence-n-nitrosamine-impurities-sartan-medicines-implementation-plan_en.pdf.
[17]
EMA.Nitrosamines EMEA-H-A5(3)-1490-Assessment report EMA/369136/2020 [EB/OL].(2020-09-07)[2024-04-01].https://www.ema.europa.eu/en/documents/referral/nitrosamines-emea-h-a53-1490-assessment-report_en.pdf.
[18]
国家药品监督管理局药品审评中心.国家药审中心关于发布《化学药物中亚硝胺类杂质研究技术指导原则(试行)》的通告[EB/OL].(2020-05-8)[2024-04-01].https://www.cde.org.cn/main/news/viewInfoCommon/776b663787e-c5a60ac744071c3714d5a.
[19]
NASR N E H, METWALY G M, AHMED E O, et al.Investigating the root cause of N-nitrosodimethylamine formation in metformin pharmaceutical products [J].Expert Opin Drug Saf, 2021, 20(7): 1-8.
[20]
JIREŠ J, GIBALA P, KALÁŠEK S, et al.The determination of two analogues of 4-(azidomethyl)-1,1'-biphenyl as potential genotoxic impurities in the active pharmaceutical ingredient of several sartans containing a tetrazole group [J].J Pham Biomed Anal, 2021, 205: 114300-114306.
[21]
WISUT W, SIRIWAN N, KACHATHONG N, et al.An update on the current status and prospects of nitrosation pathways and possible root causes of nitrosamine formation in various pharmaceuticals [J].Saudi Pharm J, 2023, 31: 295-311.
[22]
EDQM.Launches a public consultation on a new general chapter for the analysis of N-nitrosamines [EB/OL].(2020-07-04)[2024-04-01].https://www.edqm.eu/en/news/ph-eur-launches-public-consultation-new-general-chapter-analysis-n-nitrosamines.
[23]
FDA.FDA updates table of interim limits for nitrosamine impurities in ARBs [EB/OL].(2019-02-28) [2024-04-01].https://www.fda.gov/drugs/drug-safety-and-availability/fda-updates-and-press-announcements-angiotensin-ii-receptor-blocker-arb-recalls-valsartan-losartan.
[24]
张芮腾,青旺旺,廖星星,等.药物中基因毒性杂质检测方法研究进展[J].中国医院药学杂志,2021,41(3):327-332.
[25]
邓鸣,曾庆花,梁秋霞,等.HPLC-MS/MS法测定注射用盐酸头孢甲肟中7种N-亚硝胺类杂质[J].中南药学,2023,21(8):2178-12181.
[26]
陈丹,汪嘉丽.缬沙坦原料药中7个亚硝胺类基因毒性杂质测定方法的建立及评价[J].中国药物经济学,2022,17(7):97-100.
[27]
李俊,张璐,张瑄,等.GC-MS/MS测定头孢菌素类药物中8种N-亚硝胺类基因毒性杂质[J].中国药师,2022,25(2):350-354.
[28]
袁松,冯玉飞,于颖,等.UPLC-MS/MS法测定奥美沙坦酯中7个亚硝胺类基因毒性杂质[J].中国药师,2021,44(2):356-361.
2024年第55卷第6期
22
3
0
引用本文
BibTeX
文章信息
doi: 10.16522/j.cnki.cjph.2024.06.004
  • 接收时间:2023-08-01
  • 首发时间:2026-11-18
  • 出版时间:2024-06-10
补充材料
相关文章
文章信息
作者
出版历史
  • 收稿日期:2023-08-01
基金
作者信息
    1.台州市黄岩区药品不良反应监测中心,浙江 台州 318020
    2.台州市食品药品检验研究院,浙江 台州 317700
    3.台州市市场监督管理局,浙江 台州 317700
    4.台州市药学会,浙江 台州 317700
参考文献
分享链接
https://castjournals.cast.org.cn/joweb/zgyygy/CN/10.16522/j.cnki.cjph.2024.06.004
分享至
全文二维码

扫描看全文

引用本文
BibTeX
本文的引用情况
2种不同金属材料的力学参数
科
Family
属数
Number of
genus
种数
Number of
species
占总种数比例
Percentage of
total species (%)
属
Genus
种数
Number of
species
占总种数比例
Percentage of total
species (%)
鹅膏菌科Amanitaceae 2 11 5.26 鹅膏菌属 Amanita 10 4.78
小菇科 Mycenaceae 2 12 5.74 丝盖伞属 Inocybe 5 2.39
多孔菌科 Polyporaceae 8 14 6.70 蜡蘑属 Laccaria 5 2.39
红菇科 Russulaceae 3 23 11.00 小皮伞属 Marasmius 6 2.87
小菇属 Mycena 11 5.26
光柄菇属 Pluteus 5 2.39
红菇属 Russula 17 8.13
栓菌属 Trametes 5 2.39
关闭全屏